Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes

被引：264
|
作者：
van Duin, David [1 ,2 ]
Kaye, Keith S. [3 ]
Neuner, Elizabeth A. [4 ]
Bonomo, Robert A. [5 ,6 ,7 ,8 ,9 ]
机构：
[1] Cleveland Clin, Dept Infect Dis, Cleveland, OH 44106 USA
[2] Cleveland Clin, Transplant Ctr, Cleveland, OH 44106 USA
[3] Wayne State Univ, Detroit Med Ctr, Div Infect Dis, Detroit, MI USA
[4] Cleveland Clin, Dept Pharm, Cleveland, OH 44106 USA
[5] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Res Serv, Cleveland, OH USA
[6] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA
[7] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA
[8] Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA
[9] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Med Serv, Cleveland, OH USA
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2013年 / 75卷 / 02期
基金：
美国国家卫生研究院;
关键词：
Enterobacteriaceae; Carbapenem resistance; Multidrug resistance; Mortality; Bacteremia; URINARY-TRACT-INFECTIONS; CRITICALLY-ILL PATIENTS; KLEBSIELLA-PNEUMONIAE; RISK-FACTORS; POLYMYXIN-B; COLISTIN METHANESULFONATE; BETA-LACTAMASE; ANTIMICROBIAL RESISTANCE; ACINETOBACTER-BAUMANNII; K.-PNEUMONIAE;
D O I：
10.1016/j.diagmicrobio.2012.11.009
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The emergence of carbapenem resistance in Enterobacteriaceae is an important threat to global health. Reported outcomes of infections with carbapenem-resistant Enterobacteriaceae (CRE) are poor. Very few options remain for the treatment of these virulent organisms. Antibiotics which are currently in use to treat CRE infections include aminoglycosides, polymyxins, tigecycline, fosfomycin, and temocillin. In addition, the role of combination therapy, including carbapenem containing regimens, remains to be defined. There are several important concerns regarding all of these treatment options such as limited efficacy, increasing reports of resistance, and specific toxicities. Data from retrospective studies favor combination therapy over single-agent therapy for the treatment of CRE bloodstream infections. In summary, new antibiotics are greatly needed, as is additional prospective research. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码：115 / 120
页数：6
相关论文
共 50 条
  • [31] Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE)
    Dana R. Bowers
    Vanthida Huang
    Current Infectious Disease Reports, 2016, 18
  • [32] Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections A Systematic Review and Meta-Analysis
    Ni, Wentao
    Han, Yuliang
    Liu, Jie
    Wei, Chuanqi
    Zhao, Jin
    Cui, Junchang
    Wang, Rui
    Liu, Youning
    MEDICINE, 2016, 95 (11)
  • [33] Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections
    Wang, Q.
    Zhang, Y.
    Yao, X.
    Xian, H.
    Liu, Y.
    Li, H.
    Chen, H.
    Wang, X.
    Wang, R.
    Zhao, C.
    Cao, B.
    Wang, H.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2016, 35 (10) : 1679 - 1689
  • [34] Outcomes and Genetic Relatedness of Carbapenem-Resistant Enterobacteriaceae at Detroit Medical Center
    Marchaim, Dror
    Chopra, Teena
    Perez, Federico
    Hayakawa, Kayoko
    Lephart, Paul R.
    Bheemreddy, Suchitha
    Blunden, Christopher
    Hujer, Andrea M.
    Rudin, Susan
    Shango, Maryann
    Campbell, Michelle
    Varkey, Jastin
    Slim, Jessica
    Ahmad, Farah
    Patel, Diixa
    Chen, Ting-Yi
    Pogue, Jason M.
    Salimnia, Hossein
    Dhar, Sorabh
    Bonomo, Robert A.
    Kaye, Keith S.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2011, 32 (09): : 861 - 871
  • [35] Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections
    Q. Wang
    Y. Zhang
    X. Yao
    H. Xian
    Y. Liu
    H. Li
    H. Chen
    X. Wang
    R. Wang
    C. Zhao
    B. Cao
    H. Wang
    European Journal of Clinical Microbiology & Infectious Diseases, 2016, 35 : 1679 - 1689
  • [36] The carbapenem-resistant Enterobacteriaceae score: A bedside score to rule out infection with carbapenem-resistant Enterobacteriaceae among hospitalized patients
    Martin, Emily T.
    Tansek, Ryan
    Collins, Vicki
    Hayakawa, Kayoko
    Abreu-Lanfranco, Odaliz
    Chopra, Teena
    Lephart, Paul R.
    Pogue, Jason M.
    Kaye, Keith S.
    Marchaim, Dror
    AMERICAN JOURNAL OF INFECTION CONTROL, 2013, 41 (02) : 180 - 182
  • [37] Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital
    Li, Chen
    Li, Yi
    Zhao, Zhichang
    Liu, Qing
    Li, Bin
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2019, 12 (01) : 26 - 31
  • [38] Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects
    Jean, Shio-Shin
    Lee, Nan-Yao
    Tang, Hung-Jen
    Lu, Min-Chi
    Ko, Wen-Chien
    Hsueh, Po-Ren
    FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [39] Evaluation of Resistance Mechanisms in Carbapenem-Resistant Enterobacteriaceae
    Alizadeh, Naser
    Rezaee, Mohammad Ahangarzadeh
    Kafil, Hossein Samadi
    Hasani, Alka
    Barhaghi, Mohammad Hossein Soroush
    Milani, Morteza
    Sefidan, Fatemeh Yeganeh
    Memar, Mohammad Yousef
    Lalehzadeh, Aidin
    Ghotaslou, Reza
    INFECTION AND DRUG RESISTANCE, 2020, 13 : 1377 - 1385
  • [40] Carbapenem-resistant Enterobacteriaceae and endoscopy: An evolving threat
    O'Horo, John C.
    Farrell, Ann
    Sohail, M. Rizwan
    Safdar, Nasia
    AMERICAN JOURNAL OF INFECTION CONTROL, 2016, 44 (09) : 1032 - 1036
12345